Merck & Co vows to fight $8 million jury award in US Fosamax jaw damage litigation
This article was originally published in Scrip
Executive Summary
Merck & Co has lost the second trial to reach a verdict in the US over claims that it did not adequately warn about a link between its oral bisphosphonate Fosamax (alendronate) and osteonecrosis of the jaw (ONJ). But the company is challenging the verdict, wanting it set aside.